Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Corbus Pharmaceuticals Hldgs Inc (CRBP)

$8.26 +0.21 (2.61%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	153.04M
Revenue (ttm)	0.00
Net Income (ttm)	-78.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	297,800
Avg Vol	479,946
Day's Range	N/A - N/A
Shares Out	18.53M
Stochastic %K	72%
Beta	2.57
Analysts	Strong Sell
Price Target	$38.67

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Industry: Biotechnology

Sector: Healthcare

Phone: 617 963 0100

Website: www.corbuspharma.com

Address:

500 River Ridge Drive, Norwood, United States

birdmine Jun. 18 at 1:12 PM

$CRBP how long is this going to stay in the 6-8.50 range? This stock doesn’t work with data. This stock moves with history. If you haven’t already thrown a chunk of money into this heed my words and look at the history of this company.

1 · Reply

dustin46 Jun. 16 at 12:21 PM

$CRBP what’s the move today

1 · Reply

skyrockets_Inc Jun. 15 at 2:52 PM

$CRBP Bought 20 more today, Qty. 85

0 · Reply

Hepacke Jun. 12 at 6:18 PM

$CRBP Bullish

0 · Reply

giermo90 Jun. 12 at 3:58 PM

$CRBP added

0 · Reply

skyrockets_Inc Jun. 12 at 2:55 PM

$CRBP Bought more Sept $10 calls for 1.30, Qty 65

1 · Reply

dustin46 Jun. 12 at 2:39 PM

$CRBP steady as she goes .

0 · Reply

birdmine Jun. 12 at 1:37 AM

$CRBP 3 different people on the board is dropping shares. Be careful. This company is a scam.

1 · Reply

birdmine Jun. 12 at 1:31 AM

$CRBP

0 · Reply

shlomiko Jun. 10 at 2:20 PM

$CRBP

0 · Reply

Corbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer

Jun 4, 2026, 4:55 PM EDT - 15 days ago

Corbus Pharmaceuticals Holdings Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 7:30 AM EDT - 18 days ago

Corbus Pharmaceuticals Holdings Transcript: KOL event

2026-05-27T13:19:57.000Z - 23 days ago

Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush

2026-05-26T16:58:14.000Z - 24 days ago

Corbus Pharmaceuticals share selloff overdone, says Guggenheim

May 26, 2026, 8:00 AM EDT - 24 days ago

Corbus Pharmaceuticals Holdings Transcript: Study update

May 26, 2026, 8:00 AM EDT - 24 days ago

Corbus Pharmaceuticals Holdings Press release: Study update

May 26, 2026, 8:00 AM EDT - 24 days ago

Corbus Pharmaceuticals Holdings Slides: Study update

2026-05-26T11:51:41.000Z - 24 days ago

Corbus Pharmaceuticals reports updated CRB-701 Phase 1/2 data

May 26, 2026, 7:00 AM EDT - 24 days ago

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

May 26, 2026, 7:00 AM EDT - 24 days ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

2026-05-22T11:29:28.000Z - 4 weeks ago

Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho

May 21, 2026, 8:00 AM EDT - 4 weeks ago

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

KRYS

May 19, 2026, 2:05 PM EDT - 4 weeks ago

Corbus Pharmaceuticals Holdings Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 14, 2026, 8:00 AM EDT - 5 weeks ago

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

IPSC

May 14, 2026, 7:00 AM EDT - 5 weeks ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

May 13, 2026, 9:00 AM EDT - 5 weeks ago

Corbus Pharmaceuticals Holdings Transcript: AGM 2026

2026-05-13T12:01:06.000Z - 5 weeks ago

Corbus Pharmaceuticals price target lowered to $54 from $57 at Oppenheimer

May 13, 2026, 7:00 AM EDT - 5 weeks ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

2026-05-12T22:12:01.000Z - 5 weeks ago

Corbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies

May 12, 2026, 8:00 AM EDT - 5 weeks ago

Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

May 12, 2026, 8:00 AM EDT - 5 weeks ago

Corbus Pharmaceuticals Holdings Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 5 weeks ago

Corbus Pharmaceuticals Holdings Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 6 weeks ago

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

2026-04-29T09:21:07.000Z - 7 weeks ago

Corbus Pharmaceuticals initiated with a Buy at Guggenheim

2026-04-28T20:17:12.000Z - 7 weeks ago

Corbus Pharmaceuticals initiated with a Buy at Guggenheim

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy filing

2026-04-14T12:12:16.000Z - 2 months ago

Corbus Pharmaceuticals announces last person enrolled in CANYON-1 trial

2026-04-07T12:37:50.000Z - 2 months ago

Corbus reports FDA alignment for CRB-701, CMO Dominic Smethurst departure

2026-04-06T13:34:03.000Z - 2 months ago

Corbus Pharmaceuticals price target raised to $40 from $39 at Mizuho

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy filing

Mar 16, 2026, 7:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

2026-03-11T21:10:15.000Z - 3 months ago

Corbus Pharmaceuticals files $300M mixed securities shelf

Mar 11, 2026, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Registration statement: Registration Filing

2026-03-10T12:01:44.000Z - 3 months ago

Corbus Pharmaceuticals price target raised to $57 from $53 at Oppenheimer

Mar 9, 2026, 7:30 AM EDT - 3 months ago

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Mar 9, 2026, 7:30 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Annual report: Q4 2025

Mar 9, 2026, 7:30 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

Feb 25, 2026, 3:20 PM EST - 4 months ago

Corbus Pharmaceuticals Holdings Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 7:00 AM EST - 4 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

Feb 12, 2026, 8:00 AM EST - 4 months ago

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Jan 15, 2026, 11:15 AM EST - 5 months ago

Corbus Pharmaceuticals Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 5 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

Jan 5, 2026, 7:30 AM EST - 5 months ago

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 8:00 AM EST - 6 months ago

Corbus Pharmaceuticals Holdings Transcript: Study Update

Dec 11, 2025, 8:00 AM EST - 6 months ago

Corbus Pharmaceuticals Holdings Press release: Study Update

Dec 11, 2025, 7:00 AM EST - 6 months ago

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Dec 11, 2025, 7:00 AM EST - 6 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate Presentation

Dec 10, 2025, 4:01 PM EST - 6 months ago

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Dec 2, 2025, 3:50 PM EST - 7 months ago

Corbus Pharmaceuticals Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 18, 2025, 11:00 AM EST - 7 months ago

Corbus Pharmaceuticals Holdings Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 1:00 PM EST - 7 months ago

Corbus Pharmaceuticals Holdings Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 8:00 AM EST - 7 months ago

Corbus Pharmaceuticals Holdings Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Corbus Pharmaceuticals Holdings Earnings release: Q3 2025

Oct 31, 2025, 2:40 AM EDT - 8 months ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Oct 30, 2025, 4:31 PM EDT - 8 months ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Oct 19, 2025, 7:00 AM EDT - 8 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate Presentation

Oct 19, 2025, 4:00 AM EDT - 8 months ago

Corbus Pharmaceuticals Holdings Transcript: KOL Event

Oct 19, 2025, 4:00 AM EDT - 8 months ago

Corbus Pharmaceuticals Holdings Press release: KOL Event

Oct 19, 2025, 4:00 AM EDT - 8 months ago

Corbus Pharmaceuticals Holdings Slides: KOL Event

Oct 18, 2025, 3:00 AM EDT - 8 months ago

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Sep 16, 2025, 8:00 AM EDT - 9 months ago

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Aug 5, 2025, 9:00 AM EDT - 11 months ago

Corbus Pharmaceuticals Holdings Quarterly report: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 11 months ago

Corbus Pharmaceuticals Holdings Earnings release: Q2 2025

Jun 25, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 24, 2025, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 4, 2025, 4:55 PM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: Jefferies Global Healthcare Conference 2025

May 22, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 21, 2025, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 19, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

May 19, 2025, 7:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Slides: Corporate Presentation

May 6, 2025, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Earnings release: Q1 2025

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Mar 12, 2025, 1:40 PM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Annual report: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Earnings release: Q4 2024

Mar 4, 2025, 1:50 PM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 14, 2025, 7:30 AM EST - 1 year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 11, 2025, 7:30 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Feb 5, 2025, 2:30 PM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 16, 2025, 2:15 PM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 7:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Dec 3, 2024, 4:15 PM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: 7th Annual Evercore ISI HealthCONx Conference

$FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer$

Dec 3, 2024, 7:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Nov 19, 2024, 5:30 AM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 10:00 AM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

Nov 7, 2024, 9:00 AM EST - 1 year ago

Corbus Pharmaceuticals Holdings Quarterly report: Q3 2024

Nov 7, 2024, 9:00 AM EST - 1 year ago

Corbus Pharmaceuticals Holdings Earnings release: Q3 2024

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Quarterly report: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Earnings release: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Slides: Corporate Presentation

Jul 30, 2024, 8:50 AM EDT - 2 years ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jun 12, 2024, 2:40 PM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 1, 2024, 10:00 AM EDT - 2 years ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 2 years ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 9, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Earnings release: Q1 2024

May 1, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Registration statement: Registration Filing

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Earnings release: Q4 2023

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Annual report: Q4 2023

Mar 6, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Feb 28, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 6, 2024, 9:50 AM EST - 2 years ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 4:01 PM EST - 2 years ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 29, 2024, 7:18 AM EST - 2 years ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

Jan 26, 2024, 7:30 AM EST - 2 years ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Jan 23, 2024, 8:00 AM EST - 2 years ago

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Jan 9, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

birdmine Jun. 18 at 1:12 PM

1 · Reply

dustin46 Jun. 16 at 12:21 PM

$CRBP what’s the move today

1 · Reply

skyrockets_Inc Jun. 15 at 2:52 PM

$CRBP Bought 20 more today, Qty. 85

0 · Reply

Hepacke Jun. 12 at 6:18 PM

$CRBP Bullish

0 · Reply

giermo90 Jun. 12 at 3:58 PM

$CRBP added

0 · Reply

skyrockets_Inc Jun. 12 at 2:55 PM

$CRBP Bought more Sept $10 calls for 1.30, Qty 65

1 · Reply

dustin46 Jun. 12 at 2:39 PM

$CRBP steady as she goes .

0 · Reply

birdmine Jun. 12 at 1:37 AM

$CRBP 3 different people on the board is dropping shares. Be careful. This company is a scam.

1 · Reply

birdmine Jun. 12 at 1:31 AM

$CRBP

0 · Reply

shlomiko Jun. 10 at 2:20 PM

$CRBP

0 · Reply

birdmine Jun. 10 at 1:37 PM

$CRBP we may have a shot at 8$ as long as the volume stays low. If it picks up they will start diluting…heavy!!

1 · Reply

MarketBeat Jun. 9 at 9:03 AM

https://marketbeat.com/a/8702597/ $CRBP Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near

0 · Reply

birdmine Jun. 8 at 8:02 PM

$CRBP back to very low volume. It may start trickling back up. This company is a sham!!!

2 · Reply

dustin46 Jun. 5 at 5:40 PM

$CRBP averaged down.

0 · Reply

Stocksprofessional Jun. 4 at 5:44 PM

$CRBP I am officially all in.

0 · Reply

dustin46 Jun. 4 at 3:31 PM

$CRBP charts will be charts.

0 · Reply

AshleySchaeffer_BMW Jun. 4 at 3:14 PM

$CRBP insiders buying and shorts pressing, you know how this ends... see you all at $25+++

2 · Reply

marley401 Jun. 4 at 2:34 PM

$CRBP let’s get going

0 · Reply

DD_investments Jun. 4 at 1:40 PM

$CRBP not a bad buy yesterday, solid pipeline and trading around cash value

0 · Reply

skyrockets_Inc Jun. 3 at 11:49 PM

$CRBP was a good call adding those 60 Sept $10 calls earlier today :)

1 · Reply

Olivia_Strickland Jun. 3 at 10:44 PM

$CRBP +4.2% AH off the 7.38 close, light volume on it though, barely half its avg. these thin after-hours pops fade easy when nobody's there to defend the bid. no catalyst on my feed for it. what're you guys seeing? on my open list now: https://tapeboard.com/research/CRBP?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=crbp-ah-up-watch&utm_term=research

0 · Reply

DD_investments Jun. 3 at 10:09 PM

$CRBP buying after insider purchases treated me well with NUVB last year

0 · Reply

1.0.0